At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed May 12, 2026 at 16:05 ET
Zentalis reported Q1 2026 EPS of -$0.50, beating consensus of -$0.52 by 4.5%, with no revenue. The key catalyst is the selection of the 400mg QD 5:2 dose for azenosertib monotherapy in Cyclin E1-positive PROC, advancing the DENALI Phase 2 trial toward a topline readout by year-end 2026, which could support an accelerated approval pathway. Cash of $211.8M provides runway into late 2027, funding key milestones including the ASPENOVA Phase 3 trial initiation.
- Q1 2026 EPS -$0.50 vs consensus -$0.52 (4.5% beat)
- Selected 400mg QD 5:2 as pivotal dose for azenosertib monotherapy in Cyclin E1-positive PROC
- DENALI Part 2 topline readout expected by year-end 2026, potentially supporting accelerated approval
- ASPENOVA Phase 3 confirmatory trial initiated with first patient dosed
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access